Trial Profile
A retrospective comparative study of intravitreal ranibizumab and intravitreal bevacizumab for the treatment of severe retinopathy of prematurity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 15 Feb 2017 New trial record